287 Frequency and acceptance of CDSS-generated STOPP/START signals Table 2. Overview of the frequency and subsequent acceptance of generated STOPP/ START signals. Top 10 most frequently generated STOPP signals Frequency, N Acceptance, % STOPP A1 – Any drug prescribed without an evidence-based clinical indication. 1412 54.2% STOPP A3 – Any duplicate drug class prescription e.g. two concurrent NSAIDs, SSRIs, loop diuretics, ACE-I, anticoagulants 503 26.0% STOPP D5 – Benzodiazepines for ≥ 4 weeks 181 64.1% STOPP F2 – PPI for uncomplicated peptic ulcer disease or erosive peptic oesophagitis at full therapeutic dosage for > 8 weeks 146 34.9% STOPP B6 – Loop diuretic as first-line treatment for hypertension 101 22.8% STOPP C3 – Aspirin, clopidogrel, dipyridamole, VKA, direct thrombin inhibitors or factor Xa inhibitors with concurrent significant bleeding risk, i.e. uncontrolled severe hypertension, bleeding diathesis, recent non-trivial spontaneous bleeding. 75 4.0% STOPP F3 – Drugs likely to cause constipation in patients with chronic constipation where nonconstipating alternatives are available 75 20.0% STOPP G2 – Systemic corticosteroids instead of inhaled corticosteroids for maintenance therapy in moderate-severe COPD 63 6.3% STOPP C5 – Aspirin in combination with VKA, direct thrombin inhibitor or factor Xa inhibitors in patients with chronic atrial fibrillation 60 31.7% STOPP L2 – Use of regular (as distinct from PRN) opioids without concomitant laxative 56 12.5% Other STOPP criteria 793 32.2% STOPP signals that were never generated STOPP C7 – Ticlopidine in any circumstances 0 N/A STOPP D3 – Neuroleptics with moderate-marked antimuscarinic/anticholinergic effects with a history of prostatism or previous urinary retention 0 N/A STOPP D6 – Antipsychotics (i.e. other than quetiapine or clozapine) in those with parkinsonism or Lewy Body Disease 0 N/A STOPP D7 – Anticholinergics/antimuscarinics to treat extra-pyramidal side-effects of neuroleptic medications 0 N/A 4
RkJQdWJsaXNoZXIy MTk4NDMw